ID4 and breast carcinoma: More recently Brogie’s group have shown that in a large series of primary breast cancers at the Memorial Sloan Kettering Cancer Center (MSKCC) 40% of 101 TNBCs had high levels of ID4 immunoreactivity compared to only 5% of 113 HR+ve tumors [15].